Şunu aradınız:: child pugh score c (İngilizce - Maltaca)

child-pugh score ≥ 6.
punteġġ child- pugh ≥ 6.

for adults with mild hepatic impairment (child-pugh score:
id- doża rakkomandata għall- adulti b’ indeboliment tal- fwied ħafif (child- pugh score:

improvements or stabilisation were seen in child- pugh-turcotte score.
titjib jew stabilizzazzjoni ġew innutati fir-riżultati tal-punteġġ ta’ child-pugh-turcotte.

for adults with moderate hepatic impairment (child-pugh score:
id- doża rakkomandata għall- adulti b’ indeboliment tal- fwied moderat (child- pugh score:

hcv/hiv patients with cirrhosis and a child-pugh score ≥ 6.
f’pazjenti b’hcv/hiv b’ċirrożi u punteġġ child-pugh ≥ 6.

edurant has not been studied in patients with severe hepatic impairment (child-pugh score c).
edurant ma ġiex studjat f’pazjenti b’indeboliment qawwi tal- fwied (punteġġ Ċ ta’ child-pugh).

limited data exist in patients with severe hepatic impairment (child pugh score ≥ 9).
teżisti dejta limitata f’pazjenti b’indeboliment sever tal-fwied (punteġġ child pugh ta’ ≥ 9).

initiation of pegasys is contraindicated in hiv-hcv patients with cirrhosis and a child-pugh score ≥ 6
bidu ta ’ pegasys huwa kontra- indikat f’ pazjenti b’ hiv- hcv li għandhom ċirrożi u punteġġ child- pugh ta ’ ≥ 6.

severe hepatic impairment (serum albumin <25 g/l or child-pugh score  10).
indeboliment serju ħafna tal-fwied (albumina fis-serum <25 g/l jew punteġġ child-pugh  10).

alogliptin has not been studied in patients with severe hepatic impairment (child-pugh score > 9).
alogliptin ma ġiex studjat f’pazjenti b’indeboliment tal-fwied sever (punteġġ ta’ child-pugh > 9, ara sezzjoni 4.2).

there is no clinical experience in patients with severe hepatic insufficiency (child-pugh score > 9).
ma hemm l- ebda esperjenza klinika f’ pazjenti

no definitive dose recommendation can be made in patients with mild hepatic impairment (child-pugh score 5-6).
ma tista tingħata l-ebda rakkomandazzjoni definittiva ta’ doża lill-pazjenti li jbgħatu minn indeboliment epatiku ħafif (punteġġ child-pugh ta’ 5-6).

this observation is based on limited experience in 45 patients with child-pugh score ≥ 7 at the start of entecavir treatment.
din l - osservazjoni hija bbażata fuq esperjenza limitata f’ 45 pazjent b’ child pugh score ≥ 7 fil- bidu tat - trattament b’ entecavir.

no dosage adjustment is necessary for patients with mild or moderate hepatic impairment (child-pugh score 5-8).
l-ebda aġġustament fid-dożaġġ mhu meħtieġ għal pazjenti b’indeboliment minn ħafif sa moderat tal- fwied (punteġġ child-pugh 5-8).

there are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (child-pugh score > 9).
m' hemmx informazzjoni dwar il - farmakokinetiċi ta 'montelukast f' pazjenti b' insuffiċjenza epatika severa (punteġġ child- pugh > 9).

no dose reduction is required in patients with mild hepatic impairment (child-pugh score 5 to 6; see section 5.2).
ma huwa meħtieġ l-ebda tnaqqis fid-doża ta’ pazjenti b’indeboliment ħafif tal-fwied (punteġġ child-pugh minn 5 sa 6; ara sezzjoni 5.2).

alogliptin has not been studied in patients with severe hepatic impairment (child-pugh score > 9, see section 4.2).
alogliptin ma ġiex studjat f’pazjenti b’indeboliment tal-fwied sever (punteġġ ta’ child-pugh > 9, ara sezzjoni 4.2).

hepatic insufficiency no dose adjustment for sitagliptin is necessary for patients with mild or moderate hepatic insufficiency (child-pugh score ≤ 9).
indebolimenttal- fwied l- ebda aġġustament fid- doża ma huwa neċessarju għal sitagliptin għal pazjenti b’ indeboliment tal - fwied ħafif għal moderat (skor child- pugh ≤ 9).

the pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (child-pugh score 5-6) receiving a single 600 mg dose.
il- farmakokinetika ta ’ abacavir ġiet studjata f’ pazjenti b’ indeboliment epatiku ħafif (punteġġ child- pugh 5- 6) li kienu qed jirċievu doża waħda ta` 600 mg.

dosage in patients with hepatic insufficiency for adult patients with mild hepatic insufficiency (child-pugh score 5 to 6), no dosage adjustment is needed.
dożaġġ f’ pazjenti b’ insuffiċjenza tal- fwied m’ hemmx bżonn ta ’ aġġustament fid- doża għal pazjenti adulti b’ insuffiċjenza epatika ħafifa (punteġġ child- pugh 5 sa 6).